CSL Seqirus North America Tiffany Cody Phone: +1 908 370 1863 Email: Tiffany.Cody@seqirus.com Asia Pacific Hamish Walsh Phone: +61 422 424 338 Email: Hamish.Walsh@seqirus.com Global Commercial Development; UK, EMA, Argentina

Dec 13, 2024 · Why lung cancer is on the increase: Dr Clare Weeden, WEHI, Melbourne How understanding gene switching could lead to new drug classes: Dr Qi Zhang, South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide

Oct 24, 2024 · Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

Dec 13, 2024 · Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.

Oct 24, 2024 · CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.

Jan 16, 2024 · CSL Behring K.K. (Head Office: Minato-ku, Tokyo; President and Representative Director: Jean-Marc Morange) announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert® S.C. Injection 2000,” a lyophilized human C1-esterase inhibitor concentrate...

Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s new Global Headquarters and Centre for Research and Development (R&D) in the Parkville biomedical precinct in Melbourne. Part of a A$2 billion infrastructure investment program in …

Jan 16, 2024 · - The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size - IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients

Dec 12, 2022 · CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...

Nov 2, 2022 · Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...